Search Results

Containing any of the words

Only of the type

An Open-Label, Pharmacokinetic and Safety Study of Travoprost Ophthalmic Solution, 0.004% in Pediatric Glaucoma or Ocular Hypertension Patients Drug Clinical Trial

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Determine The Efficacy And Safety Of Luspatercept (Ace-536) Versus Placebo In Adults Who Require Regular Red Blood Cell Transfusions Due To Beta -Thalassemia The “BELIEVE” Trial Drug Clinical Trial

The Effect of Rectal Progesterone on the Latency period as well as Maternal and Prenatal Outcome in PPROM Between 24-33+6 Weeks Drug Clinical Trial

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Determine The Efficacy And Safety Of Luspatercept (Ace-536) Versus Placebo In Adults Who Require Regular Red Blood Cell Transfusions Due To Beta -Thalassemia The “BELIEVE” Trial Drug Clinical Trial

An Open-Label, Pharmacokinetic and Safety Study of Travoprost Ophthalmic Solution, 0.004% in Pediatric Glaucoma or Ocular Hypertension Patients Drug Clinical Trial

The Effect of Rectal Progesterone on the Latency period as well as Maternal and Prenatal Outcome in PPROM Between 24-33+6 Weeks Drug Clinical Trial

"A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition tothe Paliperidone Palmitate 3-Month Formulation in Patients with SchizophreniaPreviously Stabilized on the Paliperidone Palmitate 1-Month Formulation" Drug Clinical Trial

A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation Drug Clinical Trial

A Randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 Adjuvant Therapy in Poor Risk with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching PlaceboAfter Patients Have Achieved Complete Response with First-line Rituximab Chemotherapy Drug Clinical Trial

A Randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 Adjuvant Therapy in Poor Risk with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching PlaceboAfter Patients Have Achieved Complete Response with First-line Rituximab Chemotherapy Drug Clinical Trial